

Immunoprecipitation-Mass Spectrometry in Validation


The Antibody Society Webcast series – Antibody Validation #8

Fridtjof Lund-Johansen

Oslo University Hospital

ANTIBODY
SOCIETY


“Pillars”



A proposal for validation of antibodies

Mathias Uhlen¹, Anita Bandrowski², Steven Carr³, Aled Edwards⁴, Jan Ellenberg⁵, Emma Lundberg¹, David L Rimm⁶, Henry Rodriguez⁷, Tara Hiltke⁷, Michael Snyder⁸ & Tadashi Yamamoto⁹


Knockout: is Consensus



BUT:
The presence of extra bands is
often sample-dependent

abcam®

Knockout:
Should be combined with testing many samples




BIO-RAD


Correlation:

Analogous to fingerprint matching


Mass spec data for sample series



Staining across
Series of samples




Correlation: Currently too many matches for MS data



Overexpression: Typically validates antibodies that fail on realistic expression models

d



Research Article

Antibody performance in western blot applications is context-dependent

Biotechnology
Journal

www.biotechnology-journal.com

2014

Cajsa Älgenäs¹, Charlotta Agaton², Linn Fagerberg³, Anna Asplund⁴, Lisa Björling³, Erik Björling¹, Caroline Kampf⁴, Emma Lundberg³, Peter Nilsson³, Anja Persson¹, Kenneth Wester⁴, Fredrik Pontén⁴, Henrik Wernérus², Mathias Uhlén³, Jenny Ottosson Takanen¹ and Sophia Hober^{5,*}

82% of 1544 antibodies failed WB of endogenously expressed proteins but passed “validation” on over-expressed lysates.

IP-MS: Strong evidence for on-target binding. Off-target binding difficult to assess

NATURE METHODS
2015


Assessment of a method to characterize antibody selectivity and specificity for use in immunoprecipitation

Edyta Marcon¹, Harshika Jain², Anandi Bhattacharya², Hongbo Guo¹, Sadhna Phanse¹, Shuye Pu^{1,3}, Gregory Byram⁴, Ben C Collins⁵, Evan Dowdell⁶, Maria Fenner², Xinghua Guo¹, Ashley Hutchinson², Jacob J Kennedy⁷, Bryan Krastins⁴, Brett Larsen⁸, Zhen-Yuan Lin⁸, Mary F Lopez⁴, Peter Loppnau², Shane Miersch¹, Tin Nguyen⁹, Jonathan B Olsen⁹, Marcin Paduch⁶, Mani Ravichandran², Alma Seitova², Gouri Vadali⁴, Maryann S Vogelsang⁴, Jeffrey R Whiteaker⁷, Guoqing Zhong¹, Nan Zhong², Lei Zhao⁷, Ruedi Aebersold^{5,10,11}, Cheryl H Arrowsmith², Andrew Emili^{1,9}, Lori Frappier⁹, Anne-Claude Gingras^{8,9}, Matthias Gstaiger^{5,10}, Amanda G Paulovich⁷, Shohei Koide⁶, Anthony A Kossiakoff⁶, Sachdev S Sidhu¹, Shoshana J Wodak^{3,9,12}, Susanne Gräslund², Jack F Greenblatt^{1,9} & Aled M Edwards²

Antibody evaluation

IP gold standard: intended antigen places in top three most abundant proteins

Inconclusive: intended antigen below top three most abundant proteins



Protein arrays: We don't know yet.....


NATURE METHODS

2018


A toolbox of immunoprecipitation-grade monoclonal antibodies to human transcription factors

Anand Venkataraman¹ , Kun Yang², Jose Irizarry³, Mark Mackiewicz⁴ , Paolo Mita⁵⁻⁷ , Zheng Kuang^{6,19} , Lin Xue¹, Devlina Ghosh¹, Shuang Liu⁸, Pedro Ramos³, Shaohui Hu³, Diane Bayron Kain^{3,19}, Sarah Keegan^{5,6}, Richard Saul⁸, Simona Colantonio⁹, Hongyan Zhang⁸, Florencia Pauli-Behn⁴, Guang Song⁸, Edisa Albino³, Lillyann Asencio³, Leonardo Ramos³, Luvir Lugo³, Gloriner Morell³, Javier Rivera³, Kimberly Ruiz³, Ruth Almodovar³, Luis Nazario³, Keven Murphy³, Ivan Vargas³, Zully Ann Rivera-Pacheco³, Christian Rosa³, Moises Vargas³, Jessica McDade⁷, Brian S Clark¹, Sooyeon Yoo¹, Seva G Khambadkone¹⁰, Jimmy de Melo¹, Milanka Stevanovic¹, Lizhi Jiang¹, Yana Li¹¹, Wendy Y Yap³, Brittany Jones¹², Atul Tandon¹², Elliot Campbell^{13,14}, Gaetano T Montelione^{13,14}, Stephen Anderson^{13,14}, Richard M Myers⁴, Jef D Boeke⁵⁻⁷, David Fenyö^{5,6}, Gordon Whiteley⁹, Joel S Bader², Ignacio Pino³ , Daniel J Eichinger³ , Heng Zhu^{8,15} & Seth Blackshaw^{1,15-18}


Primary screening




“Validation” on overexpressed lysates




Consensus: Knockout - BUT - Throughput? Cost?



+



+



Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72


Carl Laflamme¹, Paul M McKeever^{2,3}, Rahul Kumar¹, Julie Schwartz¹,
Mahshad Kolahdouzan⁴, Carol X Chen¹, Zhipeng You¹, Faiza Benaliouad¹,
Opher Gileadi⁵, Heidi M McBride¹, Thomas M Durcan¹, Aled M Edwards^{1,6},
Luke M Healy⁴, Janice Robertson^{2,3}, Peter S McPherson^{1*}

ANTI
BODY
SOCI
. E T Y

>2 M Antibodies: How do we screen the whole haystack?



Parallel testing of thousands of antibodies




nature methods

BRIEF COMMUNICATION

<https://doi.org/10.1038/s41592-018-0179-8>

A high-throughput pipeline for validation of antibodies

Krzysztof Sikorski^{1,2}, Adi Mehta^{1,3,4}, Marit Inngjerdingen¹, Flourina Thakor^{3,4}, Simon Kling⁵,
Tomas Kalina⁶, Tuula A. Nyman¹, Maria Ekman Stensland¹, Wei Zhou⁷, Gustavo A. de Souza⁸,
Lars Holden⁹, Jan Stuchly⁶, Markus Templin⁵ and Fridtjof Lund-Johansen^{1,2*}




Protein
arrays


Antibody
arrays

ANTI
BODY
SOCI
. ETY


Western-MAP: “Capture WB”




Streptavidin signal





Indirect validation by correlation/clustering: r=0.95



Correlation:
 $R=0.95$ is good but not definitive




Direct specificity assessment by IP-MS




Sample

Contaminants

Native-MAP : Subcellular fractionation + Size Exclusion Chromatography




Chromatograms for individual antibodies





- Cytosol
- Cytoskeleton
- Cytoplasmic organelles
- - - Membrane
- - - Nucleus
- - - Pellet

Chromatograms for the targets of hundreds of antibodies




Native




IP-MS

Protein arrays: Intended target usually in the top five top-ranked,
But mono-specificity rare even for antibodies that stain single
bands on WB.




Antibody array pipeline

Denatured



Native



Liquid handling robotics



Automated flow cytometry



Mass spectrometry



Immunoprecipitation-Mass Spectrometry in Validation

The Antibody Society Webcast series – Antibody Validation #8

Fridtjof Lund-Johansen

Oslo University Hospital

ANTIBODY
SOCIETY